Mark Erlander - Mar 7, 2024 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Role
Chief Executive Officer, Director
Signature
/s/ Mark Erlander
Stock symbol
CRDF
Transactions as of
Mar 7, 2024
Transactions value $
$0
Form type
4
Date filed
3/7/2024, 06:39 PM
Previous filing
Mar 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRDF Stock Options Award $0 +510K +30.72% $0.00 2.17M Mar 7, 2024 Common Stock 510K $3.51 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.